

**Regd. Office :**

Zydus Tower,
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

February 14, 2012

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 2659823 //38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We are please to inform you that the Company has received final approval from the USFDA to market Pioglitazone HCl tablets in different strengths of 15 mg, 30 mg and 45 mg.

We enclose herewith a copy of press release dated February 14, 2013 under the title "**Zydus receives approval for Pioglitazone HCl tablets**" to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED

UPEN H. SHAH

Company Secretary

Encl.: As above.



Press Release

Press Release

Press Release

Press Release

Press Release



Press Release

(P)

Zydus receives final approval for Pioglitazone HCl tablets

Ahmedabad, 14 February 2013

Zydus Cadila has received the final approval from the USFDA to market Pioglitazone HCl tablets in different strengths of 15 mg, 30 mg and 45 mg. The drug falls in the anti-diabetics segment.

The estimated sales in 2012 as per IMS for Pioglitazone HCl tablets was USD 2 billion.

The group now has 75 approvals and has so far filed 170 ANDAs since the commencement of filing process in FY 2003-04.
